According to Fate Therapeutics 's latest financial reports the company's current earnings (TTM) are -$0.2 B. In 2022 the company made an earning of -$0.31 B a decrease over its 2021 earnings that were of -$0.22 B.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$0.2 B | -38.22% |
2022 | -$0.31 B | 45.36% |
2021 | -$0.22 B | 43.54% |
2020 | -$0.15 B | 53.32% |
2019 | -$96.4 M | 48.53% |
2018 | -$64.91 M | 55.7% |
2017 | -$41.69 M | 30.98% |
2016 | -$31.83 M | 14.59% |
2015 | -$27.78 M | 9.62% |
2014 | -$25.34 M | 14.83% |
2013 | -$22.07 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Becton Dickinson BDX | $1.54 B | -908.35% | ๐บ๐ธ USA |
Sarepta Therapeutics
SRPT | -$0.53 B | 173.00% | ๐บ๐ธ USA |
PTC Therapeutics
PTCT | -$0.7 B | 265.39% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | $0.33 B | -276.84% | ๐บ๐ธ USA |
Avidity Biosciences RNA | -$0.22 B | 11.40% | ๐บ๐ธ USA |